Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
about
Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formationHIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersRecombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.A self-assembling peptide acting as an immune adjuvant.Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesLong-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccineISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvantPresenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity.Vaccine adjuvants: putting innate immunity to work.The CD8⁺ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIXTM Adjuvant.Novel adjuvants & delivery vehicles for vaccines development: a road aheadMelanoma vaccines: developments over the past 10 years.Adjuvanted influenza vaccines.Adjuvants for foot-and-mouth disease virus vaccines: recent progress.Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responsesDevelopment and assessment of a new cage-like particle adjuvant.Slc15a4 function is required for intact class switch recombination to IgG2c in response to TLR9 stimulation.Translational nanoparticle engineering for cancer vaccines.Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses
P2860
Q28393754-451D5421-6B60-4A5F-98E6-CDA278825481Q28647225-CA8E3BC6-A61C-4C8F-A758-CC9063968231Q30372696-75B3D44B-F026-4C73-A43E-6388DE65C979Q31138173-DEFED6F1-123D-4783-A0E2-CA68B1F67E69Q33640064-43655ABE-4F72-4AD9-9FB7-56DFF74C66FBQ33909362-CC3DD43F-5B1E-4EE0-BC10-8CA9BC4807E6Q35100779-A125BBCC-96CB-4EAC-9305-A258CEFD8CE8Q35666175-87DFBFB8-615D-4987-BD03-79AC63DD5D6FQ36001701-4B58A1BF-9AF5-4CCB-B813-510CE13E1A10Q36009558-D5AB05B8-A835-4EEB-ADD6-1C7E30454E7FQ36085370-0ED68930-E8D0-4C5F-8CB1-866130BE09D9Q36094699-9343134D-0E89-4A45-8F31-E00D380007F6Q36168232-E2DD7902-1F88-46EB-85EF-419B2833ECDDQ37539231-A8E44966-9043-4B33-9557-B7DEF06F46BEQ37592383-3ABCCDEC-3799-44F3-AE2D-85A4425AC4A1Q37892595-806A5A08-7D2B-49D5-80AC-4B6F5659BB64Q37976540-65C90232-4955-4219-8DEF-50FCE39DEC69Q38252451-483B43C3-4D57-4910-BCD6-FE0148024F2BQ38735876-B72184BE-0D35-4194-AE91-AA3C63CEFF11Q39657741-F8A1D4CF-01DD-40EC-8771-B822929DEEB7Q40152711-5D277D8F-63A7-4B3A-B7A4-AF780134DE1AQ42183787-0AC4AE0C-8D6F-4022-B9C9-B6B3E48B8D51Q46720677-303D7C87-CF11-44FA-8E64-8DDC789030C5Q58751640-8A33A3C1-6082-43AD-A846-E4CD0C45DD4C
P2860
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
@en
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
@nl
type
label
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
@en
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
@nl
prefLabel
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
@en
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
@nl
P2093
P2860
P356
P1476
Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.
@en
P2093
Debbie Drane
Eugene Maraskovsky
Jeff Boyle
Max Schnurr
Neil C Robson
Nick S Wilson
P2860
P304
P356
10.1038/ICB.2009.21
P577
2009-04-21T00:00:00Z